Fig. 6

Remodeled ECM promotes malignancy of ovarian cancer via FAK-ERK-MMP activation. (a) Specimens from Fig. 5D were immunoassayed for p-FAK^Y397 (red), and nuclei were stained with Hoechst (blue). (b) IHC of active ERK (p-p44/42 MAPK^{Thr202/Tyr204}) in tumor lesions from WT and ApoE−/− mice with PBS or BAPN treatment two weeks after ID8 engraftment. (c) PBS or PD-325901 was administrated to ApoE−/− mice once ID8-Luciferase cells were intraperitoneally injected and treatment continued for one month. The representative images (top) and quantification data (bottom) of MMP-9 protein expression in tumor lesions two months after ID8 engraftment. (d) In vivo luciferase expression was determined two weeks or two months post treatment. Luminescence (right panel) is represented as the radiance (p/s/cm²/sr). Each experiment included data from 4 mice. Bar represents 50 μm. *P < 0.05; **P < 0.005